Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alendronate to Prevent Perimenopausal Transition Bone Loss

Trial Profile

Alendronate to Prevent Perimenopausal Transition Bone Loss

Phase of Trial: Phase II

Latest Information Update: 05 Jan 2010

At a glance

  • Drugs Alendronic acid (Primary)
  • Indications Menopause; Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jan 2010 Status changed from recruiting to completed.
    • 05 Jan 2010 Results published in Fertility and Sterility.
    • 05 Jan 2010 Primary endpoint 'Lumbar spine bone mineral density' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top